Skip to main content
. 2013 Jul 3;8(7):e68640. doi: 10.1371/journal.pone.0068640

Figure 3. Treatment with soluble TREM1-Fc does not prevent macrophage activation, injury and fibrosis in sterile kidney injury.

Figure 3

(A) Schema showing experimental design. Mice were subjected to unilateral ischemia and reperfusion injury (U-IRI) and treated daily with 40 µg/mouse of TREM1-Fc or hIgG, as control. (B) Western blot showing presence of TREM1-Fc (approximately 56kD) in 2 µl of plasma collected at day 2 from mice treated daily with 40 µg of TREM1-Fc. Anti-mouse IgG was used as endogenous control. (C) Q-PCR for different inflammatory transcripts (left) or pro-fibrotic transcripts, Collagen1a1 (Col1a1) and alpha smooth muscle actin (Acta2), from whole kidney day 5 after U-IRI. (D) Representative images (left) and quantitative graphs (right) showing+F4/80 cells (green),+αSMA (red) or collagen deposition (Sirius Red staining) day 5 after U-IRI. (*P<0.05, n = 5–7/group, 3 independent experiments; Bar marker = 50 µm; Q-PCR results were normalized to sham +hIgG).